Overall trial status: Ongoing, recruiting
Trial title: An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Medical conditions: Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis, Severe Chronic Plaque Psoriasis, Moderate to severe Chronic Plaque Psoriasis, Juvenile idiopathic Arthritis
Status in each country: Czechia:Ongoing, recruiting, Spain:Ongoing, recruiting, Poland:Ongoing, recruiting, Bulgaria:Ongoing, recruiting, Italy:Ended, Portugal:Ended, Belgium:Authorised, recruitment pending, Germany:Authorised, recruitment pending
Trial phase: Therapeutic use (Phase IV)
Therapeutic Areas: Diseases [C] - Immune System Diseases [C20]
Primary end point: Serious adverse events (SAEs), adverse events (AEs), and injection site reactions
Secondary end point: N/A
Age of participants: 18-64 years, 65+ years, 0-17 years
Gender of participants: Female, Male
Trial region: In both EEA and non-EEA
Planned number of participants: 328
Sponsor: Novartis Pharma AG
Sponsor type: Pharmaceutical company
Trial product: SECUKINUMAB, SECUKINUMAB
Results posted: No
Overall decision date: 21/08/2023
Countries decision date: IT: 09/07/2024, PT: 12/06/2024, BG: 20/09/2023, CZ: 21/08/2023, PL: 23/08/2023, ES: 22/08/2023, DE: 06/08/2026, BE: 19/11/2025
Last updated date: 06/08/2026
Es gibt noch keine Rezensionen.